RenovoRx, Inc. (RNXT): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNXT Stock Price Chart Interactive Chart >
RNXT Price/Volume Stats
| Current price | $1.98 | 52-week high | $16.74 |
| Prev. close | $2.00 | 52-week low | $1.50 |
| Day low | $1.90 | Volume | 3,900 |
| Day high | $1.98 | Avg. volume | 69,321 |
| 50-day MA | $2.29 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 17.95M |
RenovoRx, Inc. (RNXT) Company Bio
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Latest RNXT News From Around the Web
Below are the latest news stories about RenovoRx Inc that investors may wish to consider to help them evaluate RNXT as an investment opportunity.
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical TrialNEW YORK & LOS ALTOS, Calif., February 22, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center ("Columbia University"), in its ongoing TIGeR-PaC Phase 3 clinical trial. The study is evaluating the Company’s therapy platform RenovoTAMP™ (RenovoRx Trans-Arter |
RenovoRx to Host "Delivering Therapy Where it Matters" Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ETLOS ALTOS, Calif., February 03, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the "Delivering Therapy Where it Matters" fireside chat with CEO, Shaun Bagai, on Wednesday, February 23rd at 12 p.m. ET. |
RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of CancerLOS ALTOS, Calif., January 19, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Gandhi, M.D., FSIR, FSVM, a Principal Investigator in the Company’s Phase 3 TIGeR-PaC study, presented ‘Trans-arterial Treatment Option in Pancreas Cancer’ at the recent 2022 SPECTRUM Conference. Dr. Gandhi is professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and V |
RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual ConferenceLOS ALTOS, Calif., January 06, 2022--RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Shaun Bagai, Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference on behalf of RenovoRx. The conference will be held January 10-13, 2022. |
Short Squeeze Stocks: PPSI, NUZE and 3 Others Experts Think Are Ready to PopPPSI, NUZE, and three other stocks are ranked highly in Fintel's Short Squeeze Screener. |
RNXT Price Returns
| 1-mo | 15.79% |
| 3-mo | -41.25% |
| 6-mo | -72.84% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -59.09% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...